- Home
- NEOV vs ECOR Comparison
NEOV vs ECOR Comparison
Compare NEOV & ECOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEOV
- ECOR
- Stock Information
- Founded
- NEOV 2018
- ECOR 2005
- Country
- NEOV United States
- ECOR United States
- Employees
- NEOV N/A
- ECOR N/A
- Industry
- NEOV Industrial Machinery/Components
- ECOR Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- NEOV Miscellaneous
- ECOR Health Care
- Exchange
- NEOV Nasdaq
- ECOR Nasdaq
- Market Cap
- NEOV 95.7M
- ECOR 87.1M
- IPO Year
- NEOV N/A
- ECOR 2018
- Fundamental
- Price
- NEOV $5.39
- ECOR $10.94
- Analyst Decision
- NEOV Strong Buy
- ECOR Strong Buy
- Analyst Count
- NEOV 1
- ECOR 1
- Target Price
- NEOV $7.50
- ECOR $15.00
- AVG Volume (30 Days)
- NEOV 303.6K
- ECOR 157.1K
- Earning Date
- NEOV 11-08-2024
- ECOR 11-13-2024
- Dividend Yield
- NEOV N/A
- ECOR N/A
- EPS Growth
- NEOV N/A
- ECOR N/A
- EPS
- NEOV N/A
- ECOR N/A
- Revenue
- NEOV $2,471,178.00
- ECOR $23,327,000.00
- Revenue This Year
- NEOV $250.92
- ECOR $62.51
- Revenue Next Year
- NEOV $73.63
- ECOR $31.32
- P/E Ratio
- NEOV N/A
- ECOR N/A
- Revenue Growth
- NEOV N/A
- ECOR 74.10
- 52 Week Low
- NEOV $0.63
- ECOR $5.02
- 52 Week High
- NEOV $6.11
- ECOR $14.20
- Technical
- Relative Strength Index (RSI)
- NEOV 79.38
- ECOR 49.51
- Support Level
- NEOV $4.72
- ECOR $10.40
- Resistance Level
- NEOV $6.11
- ECOR $14.20
- Average True Range (ATR)
- NEOV 0.39
- ECOR 1.25
- MACD
- NEOV 0.19
- ECOR -0.14
- Stochastic Oscillator
- NEOV 76.72
- ECOR 14.21
About NEOV NeoVolta Inc.
NeoVolta Inc is engaged in designing, manufacturing and sale of high end Energy Storage System which can store and use solar energy via batteries and an inverter at a residential site. Its market place includes solar industry, installers, new construction homebuilders, home remodelers and homeowners.
About ECOR electroCore Inc.
electroCore Inc is a commercial stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology. The company's product gammaCore is Food and Drug Administration cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients and the prevention of migraine in adult patients, The use of gammaCore by adolescent patients and Treatment of hemicrania continua and paroxysmal hemicrania in adult patients.